A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with moderate to severe atopic dermatitis

Trial Profile

A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with moderate to severe atopic dermatitis

Planning
Phase of Trial: Phase II

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs MOR 106 (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Acronyms IGUANA
  • Sponsors Galapagos NV
  • Most Recent Events

    • 13 Mar 2018 According to a MorphoSys media release, company plans to initiate this trial in second quarter of 2018.
    • 20 Feb 2018 New trial record
    • 17 Feb 2018 According to a MorphoSys media release, this trial is planned to be initiated in first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top